Analyst Price Targets — MGTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 8, 2026 11:44 am | Luca Issi | RBC Capital | $26.00 | $14.66 | TheFly | MeiraGTx price target raised to $26 from $25 at RBC Capital |
| April 17, 2026 1:19 pm | — | RBC Capital | $24.00 | $10.11 | TheFly | MeiraGTx price target raised to $24 from $16 at RBC Capital |
| March 27, 2026 10:56 am | — | Piper Sandler | $26.00 | $7.62 | TheFly | MeiraGTx price target lowered to $26 from $30 at Piper Sandler |
| November 24, 2025 11:12 am | Mitchell Kapoor | H.C. Wainwright | $20.00 | $7.46 | TheFly | MeiraGTx initiated with a Buy at H.C. Wainwright |
| November 14, 2025 1:31 pm | Lisa Walter | RBC Capital | $16.00 | $8.35 | StreetInsider | MeiraGTx Holdings plc (MGTX) PT Raised at RBC Capital Amid LLY Deal |
| August 13, 2024 9:40 am | Luca Issi | RBC Capital | $9.00 | $4.02 | TheFly | MeiraGTx price target lowered to $9 from $11 at RBC Capital |
Latest News for MGTX
The mean of analysts' price targets for MeiraGTx (MGTX) points to a 128.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Stuart Naylor liquidated 27,659 shares for $409,000 on July 7, 2026, at a weighted average price of $14.80 per share. The transaction resulted in a 4% reduction of the insider's total direct equity holdings in the company.
MeiraGTx (MGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
LONDON and NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced that it has entered into an agreement with Oberland Capital Management LLC (Oberland Capital) for an investment of up to $400 million in the Company, including up to $375 million in non-dilutive capital for capped royalty payments on certain…
MeiraGTx is evolving into a late-stage, manufacturing-enabled genetic medicine company with multiple near-term regulatory catalysts. MGTX's robust manufacturing infrastructure and targeted therapies, such as Bota-vec and AAV2-hAQP1, position it for commercial inflection without mass-market commercialization burdens. Recent equity raise and anticipated milestone payments extend MGTX's cash runway through 2H 2028,…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MGTX.
U.S. House Trading
No House trades found for MGTX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.